Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Required: TACSTD2 at least 1+ expression by immunohistochemistry (≥1+ by IHC)

Subject tumors must demonstrate at least 1+ TROP2 expression by immunohistochemistry

Allowed: BRCA1 germline or somatic mutation

germline/somatic BRCA1/2 mutation carriers should have received prior PARPi therapy

Allowed: BRCA2 germline or somatic mutation

germline/somatic BRCA1/2 mutation carriers should have received prior PARPi therapy

Must have received: cytotoxic chemotherapy

Subjects must be at least 3 weeks from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy

Must have received: chemotherapy — Ovarian Cancer: at least two prior lines (frontline adjuvant plus one additional line for recurrent/progressive disease), or platinum-resistant disease (progression on platinum-containing agent or recurrence within 180 days of prior dose)

Subjects must have failed at least two prior lines of chemotherapy (i.e. frontline adjuvant chemotherapy plus one additional line for recurrent/progressive disease), or have platinumresistant disease defined as disease progression on a platinum-containing agent or recurrence within 180 days of prior dose of a platinum-containing chemotherapeutic regimen

Must have received: PARP inhibitor — Ovarian Cancer: required for germline/somatic BRCA1/2 mutation carriers

germline/somatic BRCA1/2 mutation carriers should have received prior PARPi therapy

Must have received: platinum-based chemotherapy — Mesonephric-like adenocarcinoma: at least one prior line

Subjects must have failed at least one prior line of platinum-containing chemotherapy

Must have received: FOLFIRINOX or gemcitabine-based therapy (FOLFIRINOX, gemcitabine) — Pancreatic Cancer: progressive disease after initial treatment

Subjects who have progressive disease after receiving initial treatment with either FOLFIRINOX, and/or a gemcitabine-based therapy

Cannot have received: systemic anti-cancer therapy including investigational agents

Exception: within 4 weeks of starting lymphodepleting chemotherapy

Has received systemic anti-cancer therapy including investigational agents within 4 weeks of starting lymphodepleting chemotherapy

Cannot have received: radiotherapy

Exception: within 2 weeks of start of study intervention (1-week washout permitted for palliative radiation ≤2 weeks to non-CNS disease)

Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.

Cannot have received: live vaccine

Exception: within 30 days prior to the first dose of study drug

Has received a live vaccine within 30 days prior to the first dose of study drug

Cannot have received: investigational agent or device

Exception: within 4 weeks prior to the first dose of study intervention

Is currently receiving another investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention